Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Candel Therapeutics Inc shares valued at $6,540 were sold by Nichols William Garrett on Jul 28 ’25. At $6.98 per share, Nichols William Garrett sold 937 shares. The insider’s holdings dropped to 52,493 shares worth approximately $0.26 million following the completion of this transaction.
Also, Nichols William Garrett sold 781 shares, netting a total of over 3,936 in proceeds. Following the sale of shares at $5.04 each, the insider now holds 52,493 shares.
Before that, WILLIAM GARRETT NICHOLS had added 3,593 shares to its account. In a trade valued at $17,606, the Officer bought Candel Therapeutics Inc shares for $4.90 each.
As published in a research note from BofA Securities on September 03, 2025, Candel Therapeutics Inc [CADL] has been rated down from a Buy to a Neutral and the price target has been revised to $7. As of February 20, 2025, Citigroup has initiated its “Buy” rating for CADL. Earlier on February 19, 2025, Canaccord Genuity initiated its rating. Their recommendation was “a Buy” for CADL stock.
Analyzing CADL Stock Performance
On last trading session, Candel Therapeutics Inc [NASDAQ: CADL] rose 2.07% to $4.94. The stock’s lowest price that day was $4.84, but it reached a high of $5.02 in the same session. During the last five days, there has been a surge of approximately 0.51%. Over the course of the year, Candel Therapeutics Inc shares have dropped approximately -32.14%.
Is Candel Therapeutics Inc subject to short interest?
Stocks of Candel Therapeutics Inc saw a sharp rise in short interest on 2025-08-29 jumping by 0.81 million shares to 7.27 million. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 6.46 million shares. A jump of 11.08% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 12.15 of the overall float, the days-to-cover ratio (short ratio) jumped to 12.15.
